USRE37286E1 - Method of cleansing a protein from multivalent metal ions bound thereto - Google Patents

Method of cleansing a protein from multivalent metal ions bound thereto Download PDF

Info

Publication number
USRE37286E1
USRE37286E1 US09/410,958 US41095899A USRE37286E US RE37286 E1 USRE37286 E1 US RE37286E1 US 41095899 A US41095899 A US 41095899A US RE37286 E USRE37286 E US RE37286E
Authority
US
United States
Prior art keywords
metal ions
protein
ions
multivalent metal
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US09/410,958
Other languages
English (en)
Inventor
Rainer Eketorp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Octapharma AG
Original Assignee
Pharmacia and Upjohn AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20376405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=USRE37286(E1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia and Upjohn AB filed Critical Pharmacia and Upjohn AB
Priority to US09/410,958 priority Critical patent/USRE37286E1/en
Application granted granted Critical
Publication of USRE37286E1 publication Critical patent/USRE37286E1/en
Assigned to PFIZER HEALTH AB reassignment PFIZER HEALTH AB CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: PHARMACIA AKTIEBOLAG
Assigned to BIOVITRUM AB reassignment BIOVITRUM AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PFIZER HEALTH AB
Assigned to OCTAPHARMA AG reassignment OCTAPHARMA AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BIOVITRUM AB
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation

Definitions

  • the present invention relates to a method of cleansing protein from multivalent metal ions bound thereto.
  • the metals normally derive from the various additives used when working-up and cleansing the proteins. For instance, these processes normally involve the use of filter aids and filters having a relatively high proportion of filter aids for the purpose of clear-filtering solutions in various process stages. These filter aids have often been found to contain metals which are able to bind to the protein in ion form.
  • the problems can be overcome by using other filtering methods, using filters based on inert materials. Such filters, however, are at present particularly expensive in comparison with the filter materials conventionally used.
  • the contaminating multivalent metal ions in the proteins may, for instance, consist of one or more of the metals aluminium, chromium, lead, mercury, iron, nickel, copper and magnesium. Of these metal ions, the removal of aluminium, iron and lead is the most important.
  • Aluminium which is the most common metal in the earth's crust has been assumed to constitute an ethiological factor in a number of clinical illness conditions, such as senile demens of the Alzheimer type (Crapper D. R, Kishnan S S, Quittat S. Aluminium, neurofibrillary degeneration and Alxheimer's disease. Brian 1976, 99, 67-80; and
  • the present invention provides a method of cleansing proteins of the multivalent metal ions bound thereto, so as to obtain as the end product one or more proteins in which the proportion of strongly bound multivalent metal ions is greatly reduced.
  • a protein is cleansed of multivalent metal ions bound thereto by releasing the multivalent metal ions by exchanging said multivalent ions with monovalent metal ions and removing the replaced multivalent metal ions.
  • the monovalent metal ions are subsequently also removed.
  • the monovalent metal ions used to substitute the multivalent metal ions are primarily alkali metal cations, and then particularly sodium or potassium, or ammonium cations.
  • the multivalent metal ions bound to the protein are exchanged with the monovalent metal ions, by treating a solution of the protein with a solution of a salt of a monovalent metal ion in high concentration. This process displaces the equilibrium, so that the multivalent cations are displaced by the monovalent cations.
  • the released multivalent metal cations can then be removed with the aid of one or several known processes. Processes found particularly operable in both exchange stages are diafltration and gel filtration.
  • the liquid to be filtered is caused to flow parallel with the surface of the filter and a pressure gradient is applied over the filter.
  • the pore size of the filter is selected in correspondence with the molecular size of the protein to be cleansed, so that the protein molecules are retained while the metal ions pass through the filter.
  • the size of the pores is normally of the order of nanometers.
  • a solution of salt of monovalent metal ions in high concentration is added to the protein solution, before passing the solution over the filter surface. This causes the bound multivalent metal ions to be displaced from the protein and substituted by monovalent metal ions, and the multivalent metal ions will then pass through the filter as filtrate.
  • a further solution of monovalent metal salt in a quantity corresponding to the withdrawn filtrate is then added to the resultant protein-solution concentrate, and the solution is recycled for further filtration, this process being continued until the content of multivalent metal ions has been reduced to the desired value.
  • the diafiltration process can then be continued with the addition of water instead of salt solution, the monovalent metal ions being displaced from the protein molecules and removed through the filter.
  • the same principles can be applied in gel filtration, using some known gel filtration material, e.g. a cross-linked dextran gel, such as Sephadex ® G 10 or G 25.
  • the gel filter material is selected so as to have an appropriate pore size commensurate with the molecular size of the protein to be cleansed.
  • the gel filtration process is carried out with the protein in a buffer solution containing a high proportion of monovalent metal salt, in order to displace the bound multivalent metal ions.
  • the desired cleansing effect can be achieved, in the majority of cases, by adding a sufficient quantity of monovalent metal salt to the sample to be gel-filtered.
  • the proportion of monovalent metal salt in the solution used to displace the multivalent metal ions from the protein in the diafiltration or gel filtration process can vary within relatively wide limits.
  • the absolute lowest limit of this range is determined by the physiological salt content, thus 0.9% w/v or 0.15 M.
  • the upper limit is decided, in principle, by the saturation content of the salt concerned in the solution, although other factors may also have significance. For instance, some proteins can be denatured by high salt contents. The person skilled in this art, however, will have no difficulty in finding an operable salt content on the basis of simple experiments.
  • Particularly different types of proteins can be cleansed by means of the inventive method.
  • the method has been found particularly expedient for cleansing albumin, such as human serum albumin, and gammaglobulin.
  • the invention is not restricted, however, to the cleansing of solely these proteins.
  • HSA human serum albumin
  • the apparatus include a water storage tank 1 and a supply tank 2 for 1 M sodium chloride solution.
  • the storage tanks are connected to a common conduit 7 which leads to a storage container 8 for albumin solution, via outlet pipes 3 and 5 and valves 4 and 6 respectively.
  • the albumin solution is passed from the container 8 through a pipe 9 and into an ultra-filtering device 10 , the filter of which has a porosity of 10 000 (“cut off” molecular weight).
  • a filtrate is removed from the filter device 10 through a pipe 11 and a concentrate is recirculated through a pipe 12 to the storage vessel 8 .
  • the removed filtrate has a volume of F 1 , and an equally large volume F 1 of water or salt solution is passed to the storage vessel 8 , through the pipe 7 , so as to hold the volume constant.
  • the valve 4 is closed and the valve 6 open at first, and salt solution is passed from the storage tank 2 to the storage container 8 , so as to displace the multivalent metal ions from the protein, these multivalent metal ions then being removed in the filtrate, through the pipe 11 .
  • the valve 6 is closed and the valve 4 opened, and the filtration process is continued with the addition of clean water, so as to, in turn, displace the monovalent metal ions from the protein and remove said monovalent ions in the filtrate, through the pipe 11 . Filtration with the addition of clean water is then continued until the proportion of monovalent metal ions has decreased to the desired value.
  • 15 1 M sodium chloride solution is added continuously to the albumin solution during the filtering process, wherewith the proportion of multivalent metal ions in the albumin solution, e.g. aluminium, is reduced to a value beneath 30 ⁇ g/l.
  • the input values of the metal content normally lie within the range of 200 to 1500 ⁇ g/l. The reduction of the proportion of undesirable multivalent metal ions in the protein is thus very considerable.
  • the proportions of Fe, Pb and Cr in the input albumin solution were 3.2, 0.36 and 0.6 mg/l respectively. Subsequent to treatment, these proportions were found to have reduced to 0.3, 0.08 and 0.02 mg/ml respectively.
  • the aluminium content was found to be 0.01 mg/l.
  • the solution was concentrated to an albumin content of 20%, after the dc-salting process, whereafter the aluminium content was measured to 0.02 mg/ml.
  • the solution was diafiltered with 125 liters of sodium chloride solution having the content of 2 mol/l. The solution was then de-salted with distilled water until the sodium content was less than 0.7 mg/ml. This level was reached after adding 250 liters of distilled water.
  • the solution was concentrated to an albumin content of 20% and sterile filtered and introduced into bottles (100 ml) for heat treatment at 60° C. for 10 hours.
  • the proportions in which the aforesaid metal were present in the solution were determined prior to the de-salting process and after heat-treating the bottles, the analysis results obtained being set forth in the following Table 4.
  • the present invention thus provides a simple and convenient method of removing undesirable multivalent metal ions bound to a protein.
  • the method can be applied generally for cleansing proteins and is not restricted solely to the examples described in this document. It will also be seen that further variants and modifications of the invention are possible within the scope of the following claims.
  • the proteins can be cleansed by ultrafiltration, although this method is not as rational as the described method, since it is then necessary to add further salt solution or water.
  • the inventive principles remain unchanged, however.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Water Supply & Treatment (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Detergent Compositions (AREA)
  • Manufacturing Of Electric Cables (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
US09/410,958 1989-06-27 1990-06-20 Method of cleansing a protein from multivalent metal ions bound thereto Expired - Lifetime USRE37286E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/410,958 USRE37286E1 (en) 1989-06-27 1990-06-20 Method of cleansing a protein from multivalent metal ions bound thereto

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE8902317 1989-06-27
SE8902317A SE500110C2 (sv) 1989-06-27 1989-06-27 Sätt att rena ett protein från därtill bundna flervärda metalljoner
PCT/SE1990/000442 WO1991000290A1 (en) 1989-06-27 1990-06-20 Method of cleansing proteins
US09/410,958 USRE37286E1 (en) 1989-06-27 1990-06-20 Method of cleansing a protein from multivalent metal ions bound thereto
US07/778,870 US5229498A (en) 1989-06-27 1990-06-20 Method of cleansing a protein from multivalent metal ions bound thereto

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US07/778,870 Reissue US5229498A (en) 1989-06-27 1990-06-20 Method of cleansing a protein from multivalent metal ions bound thereto

Publications (1)

Publication Number Publication Date
USRE37286E1 true USRE37286E1 (en) 2001-07-17

Family

ID=20376405

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/410,958 Expired - Lifetime USRE37286E1 (en) 1989-06-27 1990-06-20 Method of cleansing a protein from multivalent metal ions bound thereto
US07/778,870 Ceased US5229498A (en) 1989-06-27 1990-06-20 Method of cleansing a protein from multivalent metal ions bound thereto

Family Applications After (1)

Application Number Title Priority Date Filing Date
US07/778,870 Ceased US5229498A (en) 1989-06-27 1990-06-20 Method of cleansing a protein from multivalent metal ions bound thereto

Country Status (13)

Country Link
US (2) USRE37286E1 (de)
EP (1) EP0484464B2 (de)
JP (1) JPH0822873B2 (de)
AT (1) ATE132905T1 (de)
AU (1) AU632147B2 (de)
CA (1) CA2058958C (de)
DE (2) DE69024806T3 (de)
DK (1) DK0484464T4 (de)
ES (1) ES2031438T5 (de)
FI (1) FI101151B (de)
NO (1) NO300503B1 (de)
SE (1) SE500110C2 (de)
WO (1) WO1991000290A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011070399A1 (pt) 2009-12-07 2011-06-16 Universidade De Aveiro Cerâmicos produzidos a partir de escórias de incineração de resíduos sólidos

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2949846B2 (ja) * 1990-11-30 1999-09-20 吉富製薬株式会社 アルブミン製剤の保存方法
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5840851A (en) * 1993-07-23 1998-11-24 Plomer; J. Jeffrey Purification of hemoglobin
US5578564A (en) * 1993-07-23 1996-11-26 Somatogen, Inc. Nickel-free hemoglobin and methods for producing such hemoglobin
ES2103236B1 (es) * 1996-01-30 1998-04-16 Grifols Grupo Sa Albumina humana terapeutica con baja capacidad para la fijacion de aluminio.
AT403989B (de) * 1996-09-16 1998-07-27 Immuno Ag Verfahren zur herstellung eines plasmaprotein-hältigen arzneimittels
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
US6693173B2 (en) 2000-12-26 2004-02-17 Alpha Therapeutic Corporation Method to remove citrate and aluminum from proteins
GB0117879D0 (en) 2001-07-21 2001-09-12 Common Services Agency Storage of liquid compositions
WO2018033482A1 (en) 2016-08-17 2018-02-22 Boehringer Ingelheim International Gmbh Process for the preparation of highly concentrated liquid formulations containing biomolecules

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4116948A (en) * 1975-03-24 1978-09-26 Hellmut Mittenzwei Process for removal of inorganic salts from peptide/salt-containing substances
US4256631A (en) * 1979-03-22 1981-03-17 Kowa Company, Limited Process for the preparation of immunoglobulin for intravenous administration
USRE36259E (en) 1990-04-19 1999-07-27 Bayer Corporation Preparing essentially monomeric normal human serum albumin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4116948A (en) * 1975-03-24 1978-09-26 Hellmut Mittenzwei Process for removal of inorganic salts from peptide/salt-containing substances
US4256631A (en) * 1979-03-22 1981-03-17 Kowa Company, Limited Process for the preparation of immunoglobulin for intravenous administration
USRE36259E (en) 1990-04-19 1999-07-27 Bayer Corporation Preparing essentially monomeric normal human serum albumin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Welch, A.G. et al, Improvement in the Quality of Albumin Products (Stable Plasma Protein Solution) Using Ultrafiltration, XX Congress of the International Society of Blood Transfusion (British Blood Transfusion Society), London, Jul. 11-15, 1988.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011070399A1 (pt) 2009-12-07 2011-06-16 Universidade De Aveiro Cerâmicos produzidos a partir de escórias de incineração de resíduos sólidos

Also Published As

Publication number Publication date
SE500110C2 (sv) 1994-04-18
SE8902317D0 (sv) 1989-06-27
AU5946490A (en) 1991-01-17
ES2031438T1 (es) 1992-12-16
DE69024806T3 (de) 2004-10-07
JPH0822873B2 (ja) 1996-03-06
NO915101D0 (no) 1991-12-23
FI916000A0 (fi) 1991-12-19
ATE132905T1 (de) 1996-01-15
ES2031438T5 (es) 2004-09-16
CA2058958C (en) 2000-12-12
DK0484464T3 (da) 1996-02-12
DE69024806T2 (de) 1996-05-23
CA2058958A1 (en) 1990-12-28
EP0484464A1 (de) 1992-05-13
ES2031438T3 (es) 1996-03-16
SE8902317L (sv) 1990-12-28
DK0484464T4 (da) 2004-05-03
DE69024806D1 (de) 1996-02-22
NO915101L (no) 1991-12-23
JPH04506349A (ja) 1992-11-05
DE484464T1 (de) 1992-08-13
NO300503B1 (no) 1997-06-09
EP0484464B2 (de) 2004-02-11
AU632147B2 (en) 1992-12-17
WO1991000290A1 (en) 1991-01-10
FI101151B (fi) 1998-04-30
US5229498A (en) 1993-07-20
EP0484464B1 (de) 1996-01-10

Similar Documents

Publication Publication Date Title
JP4476362B2 (ja) 生物学的に活性なペプチドのミルクからの精製
USRE37286E1 (en) Method of cleansing a protein from multivalent metal ions bound thereto
EP0954528B2 (de) Methode zur chromatographischen entfernung von prionen
CA2192683C (en) Filtration
KR101528970B1 (ko) 항체의 농축 방법 및 이의 치료용 생성물
CN110526982A (zh) 一种人胰高血糖素样肽-1类似物融合蛋白的纯化方法
DE2801123A1 (de) Verfahren zur herstellung eines intravenoes applizierbaren serumeiweiss- praeparates
EP2072056B1 (de) Verfahren zur Gewinnung von hocheffizientem Humanalbumin zur Verwendung in der Entgiftungstherapie
AU2005223418B2 (en) Albumin-purification method comprising a nanofiltration step, solution, and composition for therapeutic use containing same
GB2179947A (en) Process for the extraction of proteins from milk
EP3362464B1 (de) Verfahren zur extraktion von proteinen aus blutplasma
JPS63503352A (ja) タンパク質の精製
JPH0533239B2 (de)
JP3009242B2 (ja) 精製単量体健康人血清アルブミン（ヒト）
EP3418290A1 (de) Verfahren zur entfernung von verunreinigungen
CN110678481B (zh) 用于纯化白蛋白的方法
US20040251202A1 (en) Method of separating protein from animal milk
DE69416103T2 (de) Verdrängungschromatographisches verfahren und gereinigtes hämoglobin
JP3106509B2 (ja) 抗ヒトリンパ球抗体の製造方法
Zondek et al. The preparation of concentrated antigonadotropic factor (antiprolan)

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 12

AS Assignment

Owner name: PFIZER HEALTH AB, SWEDEN

Free format text: CHANGE OF NAME;ASSIGNOR:PHARMACIA AKTIEBOLAG;REEL/FRAME:016263/0753

Effective date: 20041020

AS Assignment

Owner name: BIOVITRUM AB, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PFIZER HEALTH AB;REEL/FRAME:016274/0340

Effective date: 20050427

AS Assignment

Owner name: OCTAPHARMA AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIOVITRUM AB;REEL/FRAME:016283/0261

Effective date: 20050513